ILIAS Biologics, Inc. announced that its project to develop exosome-based IBD treatment has been selected as the winner of the 2022 KDDF National New Drug Development Project and has signed a contract with KDDF. Please find the details in the below news link.  

(Newsis)ILIAS Biologics, Inc. signed a contract with KDDF to develop an exosome-based IDB treatment